PL1677818T3 - Stabilne kompozycje wodne zawierające G-CSF - Google Patents
Stabilne kompozycje wodne zawierające G-CSFInfo
- Publication number
- PL1677818T3 PL1677818T3 PL04790683T PL04790683T PL1677818T3 PL 1677818 T3 PL1677818 T3 PL 1677818T3 PL 04790683 T PL04790683 T PL 04790683T PL 04790683 T PL04790683 T PL 04790683T PL 1677818 T3 PL1677818 T3 PL 1677818T3
- Authority
- PL
- Poland
- Prior art keywords
- csf
- stable aqueous
- containing compositions
- compositions
- lyophilisates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10348550A DE10348550A1 (de) | 2003-10-20 | 2003-10-20 | Stabile wässrige G-CSF-haltige Zusammensetzungen |
| PCT/EP2004/011875 WO2005039620A1 (de) | 2003-10-20 | 2004-10-20 | Stabile wässrige g-csf-haltige zusammensetzungen |
| EP04790683A EP1677818B1 (de) | 2003-10-20 | 2004-10-20 | Stabile wässrige g-csf-haltige zusammensetzungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1677818T3 true PL1677818T3 (pl) | 2012-07-31 |
Family
ID=34484809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04790683T PL1677818T3 (pl) | 2003-10-20 | 2004-10-20 | Stabilne kompozycje wodne zawierające G-CSF |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080026046A1 (pl) |
| EP (1) | EP1677818B1 (pl) |
| JP (1) | JP2007509101A (pl) |
| AT (1) | ATE535251T1 (pl) |
| DE (1) | DE10348550A1 (pl) |
| PL (1) | PL1677818T3 (pl) |
| WO (1) | WO2005039620A1 (pl) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE202006020194U1 (de) * | 2006-03-01 | 2007-12-06 | Bioceuticals Arzneimittel Ag | G-CSF-Flüssigformulierung |
| TW200806315A (en) * | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
| AU2008235044B2 (en) * | 2007-04-05 | 2011-08-25 | Sandoz Ag | Stable aqueous G-CSF formulations |
| PL2076243T3 (pl) | 2007-08-27 | 2015-04-30 | Ratiopharm Gmbh | Płynna formulacja G-CSF |
| DE202007018629U1 (de) * | 2007-08-27 | 2008-12-24 | Biogenerix Ag | Flüssigformulierung von G-CSF |
| CA2696594C (en) * | 2007-08-27 | 2019-03-19 | Biogenerix Ag | Liquid formulation of g-csf conjugate |
| SI2575870T1 (sl) | 2010-06-04 | 2017-01-31 | Wyeth Llc | Formulacije cepiva |
| EP2399572A1 (en) | 2010-06-22 | 2011-12-28 | Sandoz AG | Long-term storage of non-glycosylated recombinant human G-CSF |
| AR083006A1 (es) * | 2010-09-23 | 2013-01-23 | Lilly Co Eli | Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas |
| AU2014231816B2 (en) * | 2013-03-12 | 2016-11-03 | Sumitomo Dainippon Pharma Co., Ltd. | Liquid aqueous composition |
| WO2015089105A1 (en) | 2013-12-09 | 2015-06-18 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
| BR112022013730A2 (pt) * | 2020-01-13 | 2022-10-11 | Aptevo Res & Development Llc | Métodos e composições para prevenir a adsorção de proteínas terapêuticas aos componentes do sistema de distribuição de drogas |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3273597D1 (en) * | 1981-11-28 | 1986-11-06 | Sunstar Kk | Pharmaceutical composition containing interferon in stable state |
| JPH0645551B2 (ja) * | 1986-01-07 | 1994-06-15 | 塩野義製薬株式会社 | インタ−ロイキン−２組成物 |
| US5151265A (en) * | 1987-11-03 | 1992-09-29 | Genentech, Inc. | Gamma interferon formulation |
| US5078997A (en) * | 1988-07-13 | 1992-01-07 | Cetus Corporation | Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers |
| US5350741A (en) * | 1988-07-30 | 1994-09-27 | Kanji Takada | Enteric formulations of physiologically active peptides and proteins |
| US5104651A (en) * | 1988-12-16 | 1992-04-14 | Amgen Inc. | Stabilized hydrophobic protein formulations of g-csf |
| JP3249147B2 (ja) * | 1990-06-01 | 2002-01-21 | キリン−アムジエン・インコーポレーテツド | 生理活性蛋白含有経口製剤 |
| DE4242919A1 (de) * | 1992-12-18 | 1994-06-23 | Boehringer Mannheim Gmbh | Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF |
| DE4242863A1 (de) * | 1992-12-18 | 1994-06-23 | Boehringer Mannheim Gmbh | Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF |
| DE19549232C2 (de) * | 1995-12-20 | 1998-05-20 | Boehringer Mannheim Gmbh | Verwendung von G-CSF in Kombination mit einem Chemotherapeutikum bei der Behandlung von Erkrankungen, die eine periphere Stammzelltransplantation erfordern |
| US7001892B1 (en) * | 1999-06-11 | 2006-02-21 | Purdue Research Foundation | Pharmaceutical materials and methods for their preparation and use |
| WO2001024814A1 (en) * | 1999-10-04 | 2001-04-12 | Chiron Corporation | Stabilized liquid polypeptide-containing pharmaceutical compositions |
| US6875432B2 (en) * | 2000-10-12 | 2005-04-05 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
-
2003
- 2003-10-20 DE DE10348550A patent/DE10348550A1/de not_active Withdrawn
-
2004
- 2004-10-20 AT AT04790683T patent/ATE535251T1/de active
- 2004-10-20 JP JP2006536040A patent/JP2007509101A/ja active Pending
- 2004-10-20 EP EP04790683A patent/EP1677818B1/de not_active Expired - Lifetime
- 2004-10-20 WO PCT/EP2004/011875 patent/WO2005039620A1/de not_active Ceased
- 2004-10-20 PL PL04790683T patent/PL1677818T3/pl unknown
- 2004-10-20 US US10/576,864 patent/US20080026046A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007509101A (ja) | 2007-04-12 |
| US20080026046A1 (en) | 2008-01-31 |
| WO2005039620A1 (de) | 2005-05-06 |
| DE10348550A1 (de) | 2005-06-16 |
| EP1677818B1 (de) | 2011-11-30 |
| ATE535251T1 (de) | 2011-12-15 |
| EP1677818A1 (de) | 2006-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200732349A (en) | Anti-OX40L antibodies and methods using same | |
| UA86591C2 (ru) | Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе | |
| TW200505875A (en) | Novel compounds | |
| ZA200702226B (en) | Compounds, compositions containing them, preparations thereof and uses thereof II | |
| TW200611910A (en) | Interferon-alpha polypeptides and conjugates | |
| WO2006002840A3 (de) | Aerosolsuspensionsformulierungen mit tg 227 ea oder tg 134 a als treibmittel | |
| MXPA03010158A (es) | Sulfonamidas. | |
| MX2007008723A (es) | Polipeptidos de yersinia spp y metodos de uso. | |
| JO2578B1 (en) | Compounds Theophene benzimidazole | |
| PL1677818T3 (pl) | Stabilne kompozycje wodne zawierające G-CSF | |
| TW200738751A (en) | Anti-EphrinB2 antibodies and methods using same | |
| TW200716605A (en) | 2,6-quinolinyl derivatives, processes for preparing them and their uses | |
| IL179883A0 (en) | 4,6-disubstituted pyrimidine derivatives and pharmaceutical compositions containing the same | |
| TW200738283A (en) | Formulations of conjugated estrogens and bazedoxifene | |
| IS2799B (is) | Kladribínefnablöndur til inngjafar um munn | |
| TW200605863A (en) | Bazedoxifene acetate formulations | |
| TW200517117A (en) | Stabilized compositions containing an oxygen-labile active agent | |
| SI2142174T1 (sl) | Stabilne vodne G-CSF formulacije | |
| TW200630343A (en) | 2-Alkoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof | |
| WO2006133006A3 (en) | 1-methyl-1h-pyrazole-4-carboxamides useful as cancer chemotherapeutic agents | |
| ZA200604874B (en) | Pharmaceutical compositions | |
| MXPA05012742A (es) | Composiciones de tratamiento para el cabello. | |
| TW200728205A (en) | Alumina particles and methods of making the same | |
| WO2002089740A3 (en) | Sulfonamides | |
| TW200738244A (en) | 20-Alkyl, gemini vitamin D3 compounds and methods of use thereof |